A detailed history of Credit Suisse Ag transactions in Regenxbio Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 41,704 shares of RGNX stock, worth $399,941. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,704
Previous 41,704 -0.0%
Holding current value
$399,941
Previous $748,000 17.38%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$12.89 - $20.82 $60,750 - $98,124
4,713 Added 12.74%
41,704 $748,000
Q3 2023

Nov 13, 2023

SELL
$16.46 - $19.99 $132,782 - $161,259
-8,067 Reduced 17.9%
36,991 $608,000
Q2 2023

Aug 11, 2023

BUY
$17.23 - $21.71 $205,967 - $259,521
11,954 Added 36.11%
45,058 $900,000
Q1 2023

May 10, 2023

BUY
$18.08 - $24.55 $162 - $220
9 Added 0.03%
33,104 $625,000
Q4 2022

Feb 13, 2023

SELL
$20.4 - $24.73 $174,012 - $210,946
-8,530 Reduced 20.49%
33,095 $750,000
Q3 2022

Nov 10, 2022

BUY
$22.29 - $35.04 $174,307 - $274,012
7,820 Added 23.13%
41,625 $1.1 Million
Q2 2022

Aug 12, 2022

SELL
$19.35 - $35.04 $81,889 - $148,289
-4,232 Reduced 11.13%
33,805 $835,000
Q1 2022

May 16, 2022

BUY
$24.62 - $34.31 $42,961 - $59,870
1,745 Added 4.81%
38,037 $1.26 Million
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $53,315 - $71,134
1,766 Added 5.11%
36,292 $1.19 Million
Q3 2021

Nov 12, 2021

SELL
$29.09 - $45.68 $118,279 - $185,734
-4,066 Reduced 10.54%
34,526 $1.45 Million
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $26,519 - $33,072
-817 Reduced 2.07%
38,592 $1.5 Million
Q1 2021

May 14, 2021

SELL
$33.61 - $49.95 $683,224 - $1.02 Million
-20,328 Reduced 34.03%
39,409 $1.35 Million
Q4 2020

Feb 12, 2021

SELL
$26.52 - $49.35 $12.4 Million - $23.1 Million
-467,506 Reduced 88.67%
59,737 $2.71 Million
Q3 2020

Nov 13, 2020

SELL
$27.01 - $40.26 $263,482 - $392,736
-9,755 Reduced 1.82%
527,243 $14.5 Million
Q2 2020

Aug 12, 2020

BUY
$27.75 - $43.44 $955,488 - $1.5 Million
34,432 Added 6.85%
536,998 $19.8 Million
Q1 2020

May 13, 2020

SELL
$21.5 - $54.2 $122,141 - $307,910
-5,681 Reduced 1.12%
502,566 $16.3 Million
Q4 2019

Feb 12, 2020

BUY
$34.54 - $44.87 $704,374 - $915,033
20,393 Added 4.18%
508,247 $20.8 Million
Q3 2019

Nov 12, 2019

SELL
$31.84 - $50.88 $212,086 - $338,911
-6,661 Reduced 1.35%
487,854 $17.4 Million
Q2 2019

Aug 14, 2019

SELL
$42.0 - $59.29 $32,592 - $46,009
-776 Reduced 0.16%
494,515 $25.4 Million
Q1 2019

May 14, 2019

SELL
$40.82 - $62.45 $652,834 - $998,762
-15,993 Reduced 3.13%
495,291 $28.4 Million
Q4 2018

Feb 13, 2019

BUY
$39.11 - $75.15 $2.6 Million - $4.99 Million
66,373 Added 14.92%
511,284 $21.4 Million
Q3 2018

Nov 13, 2018

BUY
$65.0 - $82.15 $6.91 Million - $8.74 Million
106,333 Added 31.41%
444,911 $33.6 Million
Q2 2018

Aug 14, 2018

BUY
$27.2 - $74.35 $8.38 Million - $22.9 Million
308,023 Added 1008.09%
338,578 $24.3 Million
Q1 2018

May 15, 2018

BUY
$24.05 - $37.5 $62,962 - $98,175
2,618 Added 9.37%
30,555 $912,000
Q4 2017

Feb 14, 2018

SELL
$26.0 - $34.6 $174,902 - $232,754
-6,727 Reduced 19.41%
27,937 $930,000
Q3 2017

Nov 14, 2017

BUY
$18.0 - $32.95 $115,830 - $212,033
6,435 Added 22.8%
34,664 $1.14 Million
Q2 2017

Aug 14, 2017

BUY
N/A
28,229
28,229 $557,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $415M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.